Globus Medical/$GMED
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Globus Medical
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
- Ticker
- $GMED
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 6,000
- Headquarters
- Audubon, United States
- Website
- www.globusmedical.com
Globus Medical Metrics
BasicAdvanced
$10B
19.96
$3.91
0.95
-
Price and volume
Market cap
$10B
Beta
0.95
52-week high
$101.40
52-week low
$59.51
Average daily volume
1.4M
Financial strength
Current ratio
4.622
Quick ratio
2.784
Long term debt to equity
0.02
Total debt to equity
0.023
Profitability
EBITDA (TTM)
1,010.295
Gross margin (TTM)
68.98%
Net profit margin (TTM)
17.03%
Operating margin (TTM)
23.22%
Effective tax rate (TTM)
18.89%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
8.74%
Return on equity (TTM)
11.81%
Valuation
Price to earnings (TTM)
19.963
Price to revenue (TTM)
3.346
Price to book
2.2
Price to tangible book (TTM)
3.97
Price to free cash flow (TTM)
14.109
Free cash flow yield (TTM)
7.09%
Free cash flow per share (TTM)
5.532
Growth
Revenue change (TTM)
19.74%
Earnings per share change (TTM)
51.94%
3-year revenue growth (CAGR)
42.06%
10-year revenue growth (CAGR)
18.96%
3-year earnings per share growth (CAGR)
25.03%
10-year earnings per share growth (CAGR)
12.26%
What the Analysts think about Globus Medical
Analyst ratings (Buy, Hold, Sell) for Globus Medical stock.
Analyst projections of the future price of Globus Medical stock.
Bulls say / Bears say
Q2 sales grew 9% excluding Nevro, with US Spine up 7%, International Spine up 14% and trauma up 31%. This broad growth supports the case that Globus is gaining share across several businesses. (Globus Medical)
Adjusted gross margin rose 200 basis points to 69.4%, and non-GAAP EPS increased 55.8% in Q2. Globus raised its full-year EPS guidance while holding its revenue outlook steady, pointing to stronger profitability and operating leverage. (Globus Medical)
EU and UK clearance for Excelsius3D lets Globus begin commercialising its imaging system in those markets. Linking the system with its robotic navigation platform could strengthen the company’s surgical technology offering and support international growth. (MassDevice)
Nevro sales fell 14.3% year on year in Q2 and edged down sequentially. Management is targeting a return to historical trial volumes only by late Q4, leaving the acquired business’s recovery uncertain. (StockAnalysis)
Enabling Technologies revenue fell 26% as Globus shifted towards leasing and rentals rather than outright system sales. Management identified this strategy change as a downside risk to its revenue outlook, so the new model may weigh on near-term reported growth. (StockAnalysis)
More competitors in surgical robotics have lengthened hospital deal cycles, as buyers take time to compare available systems. That could delay placements and slow adoption of Globus’s enabling technology. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
Globus Medical Financial Performance
Revenues and expenses
Globus Medical Earnings Performance
Company profitability
Upcoming events
No upcoming events
Globus Medical News
AllArticlesVideos
Funds containing Globus Medical
AllUSDEURGBP
Fund name | Fund size | $GMED weighting |
|---|---|---|
L&G ROBO Global Robotics and Automation$ROBO | $1.7B | 1.37% |
L&G ROBO Global Robotics and Automation£ROBG | $1.7B | 1.37% |
iShares Ageing Population$AGED | $953M | 0.49% |
iShares Ageing Population€AGED | $903M | 0.49% |
iShares Ageing Population£AGES | $953M | 0.49% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.